Multiple myeloma: open trials in France

94 open trials have a site in France. Registry data; only the trial team decides who can take part.

NCT05137054
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Trial Treatment · Phase 1 · Regeneron Pharmaceuticals
Centre Hospitalier Universitaire D'Angers, Angers · Assistance Publique Hopitaux De Paris, Creteil Cedex · Centre Hospitalier Universitaire de Lille, Lille · Centre Hospitalier Universitaire De Montpellier, Montpellier Cedex 5 · Centre Hospitalier Universitaire de Nantes, Nantes · Assistance Publique Hopitaux de Paris, Paris · Centre Hospitalier Universitaire de Poitiers, Poitiers · Institut Gustave Roussy, Villejuif
Registry updated 2026-11-05
NCT05583617
A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
Trial Treatment · Phase 1/2 · Hoffmann-La Roche
Hospices Civils de Lyon, Pierre-Bénite · Institut Universitaire Du Cancer Toulouse-Oncopole, Toulouse Cedex 9 · Centre Hospitalier Regional Universitaire De Tours, Tours Cedex 9 · Institut Gustave Roussy, Villejuif
Registry updated 2026-11-05
NCT07222761
A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Trial Treatment · Phase 3 · Regeneron Pharmaceuticals
Centre Hospitalier Victor Dupouy, Argenteuil Cedex · Centre Hospitalier Métropole Savoie, Chambéry · Centre Leon Berard, Lyon · Centre Hospitalier Universitaire de Nantes, Nantes · Assistance Publique Hopitaux de Paris, Paris · Hospices Civils de Lyon, Pierre-Bénite · Centre Hospitalier Universitaire de Poitiers, Poitiers · Centre Hospitalier Universitaire De Toulouse, Toulouse Cedex 9 · Centre Hospitalier Régional Universitaire de Tours, Tours · CHRU De Nancy, Vandoeuvre Les Nancy Cedex · Institut Gustave Roussy, Villejuif
Registry updated 2026-11-04
NCT07393282
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Trial Treatment · Phase 3 · Regeneron Pharmaceuticals
Centre Hospitalier Universitaire D'Angers, Angers · Centre Hospitalier De Cannes Simone Veil, Cannes Cedex · Groupement Des Hopitaux De L'Institut Catholique De Lille, Lille Cedex · Centre Leon Berard, Lyon · Centre Hospitalier Universitaire De Montpellier, Montpellier Cedex 5 · Centre Hospitalier Universitaire de Nantes, Nantes · Assistance Publique Hopitaux de Paris, Paris · Assistance Publique Hopitaux De Paris, Paris Cedex 13 · Centre Hospitalier Universitaire De Bordeaux, Pessac Cedex · Centre Hospitalier Universitaire de Poitiers, Poitiers · Centre Henri Becquerel, Rouen Cedex · Institut Curie, Saint-Cloud · Centre Hospitalier Universitaire De Toulouse, Toulouse Cedex 9 · Institut Gustave Roussy, Villejuif
Registry updated 2026-11-04
NCT04634552
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 2 · Janssen Research & Development, LLC
Assistance Publique Hopitaux De Paris, Creteil Cedex · Centre Hospitalier Universitaire De Montpellier, Montpellier Cedex 5 · Centre Hospitalier Universitaire de Nantes, Nantes · Centre Hospitalier Universitaire de Bordeaux, Pessac · Centre Hospitalier Lyon-Sud, Pierre-Bénite · Institut Universitaire Du Cancer Toulouse-Oncopole, Toulouse Cedex 9
Registry updated 2026-11-03
NCT05201781
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Trial Treatment · Phase 4 · Janssen Research & Development, LLC
Centre Hospitalier Universitaire De Lille, Lille Cedex · Centre Hospitalier Universitaire de Nantes, Nantes · Assistance Publique Hopitaux de Paris, Paris · Hospices Civils de Lyon, Pierre-Bénite · Centre Hospitalier Universitaire de Poitiers, Poitiers
Registry updated 2026-11-03
NCT05552222
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
Assistance Publique Hopitaux De Paris, Creteil · Centre Hospitalier Universitaire de Dijon, Dijon · Centre Hospitalier Universitaire de Lille, Lille · Centre Hospitalier Universitaire de Nantes, Nantes · Assistance Publique Hopitaux de Paris, Paris · Centre Hospitalier Universitaire de Bordeaux, Pessac · Hospices Civils de Lyon, Pierre-Bénite · Centre Hospitalier Universitaire de Poitiers, Poitiers · Centre Hospitalier Universitaire de Rennes, Rennes · Institut de Cancérologie Strasbourg Europe, Strasbourg · Les Hopitaux Universitaires De Strasbourg, Strasbourg Cedex 2 · Centre Hospitalier Universitaire De Toulouse, Toulouse Cedex 9
Registry updated 2026-11-03
NCT05652335
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
Trial Treatment · Phase 1 · Janssen Research & Development, LLC
Centre Hospitalier Universitaire de Nantes, Nantes · Centre Hospitalier Lyon-Sud, Pierre-Bénite · Centre Hospitalier Universitaire de Rennes, Rennes · Institut Universitaire du Cancer Toulouse - Oncopole, Toulouse
Registry updated 2026-11-03
NCT07258511
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
Assistance Publique Hopitaux De Paris, Creteil · Centre Hospitalier Universitaire de Lille, Lille · CHRU De Nancy, Nancy Cedex · Centre Hospitalier Universitaire de Nantes, Nantes · Assistance Publique Hopitaux de Paris, Paris · Centre Hospitalier Universitaire de Bordeaux, Pessac · Hospices Civils de Lyon, Pierre-Bénite · Centre Hospitalier Universitaire de Poitiers, Poitiers · Centre Hospitalier Universitaire De Toulouse, Toulouse Cedex 9 · Centre Hospitalier Régional Universitaire de Tours, Tours
Registry updated 2026-11-03
NCT07589634
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
Trial Treatment · Phase 2 · Janssen Research & Development, LLC
Centre Hospitalier Victor Dupouy, Argenteuil · Centre Hospitalier de la Cote Basque, Bayonne · CHU de Grenoble, La Tronche · Centre de Cancérologie de la Sarthe, Le Mans · CHU Nantes-Hotel Dieu, Nantes · Centre Hospitalier de Quimper Cornouaille, Quimper
Registry updated 2026-11-03
NCT07665450
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
Trial Treatment · Phase 3 · Janssen Research & Development, LLC
Hopital Claude Huriez, Lille · CHU de Montpellier Hôpital Saint Eloi, Montpellier · CHU Nantes, Nantes · APHP - Hôpital Saint Antoine, Paris · CHU de Bordeaux - Hospital Haut-Leveque, Pessac · CHU Lyon Sud, Pierre-Bénite · IUCT Oncopole - Institut Claudius Regaud, Toulouse · CHRU Tours Hopital Bretonneau, Tours · CHU Nancy-Brabois, Vandœuvre-lès-Nancy
Registry updated 2026-11-03
NCT05519085
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Trial Treatment · Phase 3 · Celgene
Clermont-Ferrand · Lille · Limoges · Lyon Cedex08 · Nantes · Nîmes · Paris · Pessac · Strasbourg · Tours
Registry updated 2026-10-30
NCT06106945
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
Trial Treatment · Phase 1/2 · AstraZeneca
Lille · Nantes
Registry updated 2026-10-30
NCT07284758
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Trial Treatment · Phase 2 · C4 Therapeutics, Inc.
Centre Hospitalier de la Cote Basque, Bayonne · Institut Paoli-Calmettes, Marseille · Hospices Civils de Lyon, Pierre-Bénite · Centre Henri Becquerel, Rouen Cedex · Centre Hospitalier Universitaire De Toulouse, Toulouse Cedex 9 · Centre Hospitalier Régional Universitaire de Tours, Tours · Institut Gustave Roussy, Villejuif
Registry updated 2026-10-30
NCT06615479
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
Trial Treatment · Phase 3 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
CHU Henri Mondor, Créteil Cedex · Centre Hospitalier Universitaire De Lille, Lille Cedex · CHU Nantes, Nantes · Assistance Publique Hopitaux de Paris, Paris · Hospices Civils de Lyon, Pierre-Bénite
Registry updated 2026-10-29
NCT05623020
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Trial Treatment · Phase 3 · Pfizer
Centre Hospitalier Universitaire de Nantes, Nantes · Centre Hospitalier Universitaire de Nice, Nice · Hopital Saint Antoine, Paris Cedex 12 · Centre Hospitalier Universitaire de Poitiers, Poitiers · Centre Hospitalier Universitaire De Toulouse, Toulouse Cedex 9 · CHU Bretonneau, Tours · Institut Gustave Roussy, Villejuif
Registry updated 2026-10-27
NCT06953960
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Trial Treatment · Phase 1/2 · AbbVie
Centre Hospitalier Universitaire De Montpellier, Montpellier Cedex 5 · Centre Hospitalier Universitaire de Nantes, Nantes · Assistance Publique Hopitaux de Paris, Paris · Centre Hospitalier Universitaire de Poitiers, Poitiers · Oncopole Claudius Regaud, Toulouse
Registry updated 2026-10-27
NCT04973605
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
Trial Treatment · Phase 1/2 · BeOne Medicines
Centre Hospitalier Universitaire De Lille, Lille Cedex · Centre Hospitalier Universitaire de Nantes, Nantes · Centre Hospitalier Universitaire de Poitiers, Poitiers
Registry updated 2026-10-26
NCT05651932
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Trial Treatment · Phase 1 · K36 Therapeutics, Inc.
Centre Hospitalier Universitaire De Lille, Lille Cedex · Centre Hospitalier Universitaire de Nantes, Nantes · Centre Hospitalier Universitaire de Poitiers, Poitiers · Institut Universitaire Du Cancer Toulouse-Oncopole, Toulouse Cedex 9
Registry updated 2026-10-22
NCT07735637
A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
Trial Treatment · Phase 3 · AstraZeneca
Lille · Nantes · Paris · Toulouse
Registry updated 2026-10-21
NCT04910568
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 1 · Genentech, Inc.
Hospital Hotel Dieu, Nantes · Hopital Saint Louis, Paris · Centre Hospitalier Universitaire de Poitiers, Poitiers
Registry updated 2026-10-20
2025-523815-12-00
A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma
Trial Treatment · Phase 3 · Janssen Cilag International
Centre Hospitalier Universitaire Amiens Picardie, Amiens Cedex 1 · Centre Hospitalier Universitaire de Lille, Lille · Centre Hospitalier Universitaire De Montpellier, Montpellier Cedex 5 · Centre Hospitalier Universitaire de Nantes, Nantes · Centre Hospitalier Universitaire de Bordeaux, Pessac · Hospices Civils de Lyon, Pierre-Bénite · Centre Hospitalier Universitaire de Poitiers, Poitiers · Centre Hospitalier Universitaire De Toulouse, Toulouse Cedex 9 · Centre Hospitalier Régional Universitaire de Tours, Tours · Institut Gustave Roussy, Villejuif
Registry updated 2026-10-19
NCT07095452
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Trial Treatment · Phase 2/3 · AbbVie
Centre Hospitalier Universitaire De Caen Normandie, Caen Cedex 9 · L’Hopital Alexandra Lepeve, Dunkirk Cedex 1 · Centre Hospitalier Annecy Genevois, Epagny Metz-tessy · Centre Hospitalier Universitaire de Lille, Lille · Centre Hospitalier Universitaire De Montpellier, Montpellier Cedex 5 · Centre Hospitalier Universitaire de Nantes, Nantes · Assistance Publique Hopitaux de Paris, Paris · Centre Hospitalier Universitaire de Bordeaux, Pessac · Hospices Civils de Lyon, Pierre-Bénite · Centre Hospitalier Universitaire de Poitiers, Poitiers · Centre Hospitalier Universitaire de Saint Etienne, Saint-Priest-en-Jarez · Centre Hospitalier Universitaire De Toulouse, Toulouse Cedex 9 · Centre Hospitalier Régional Universitaire de Tours, Tours · Centre Hospitalier Bretagne Atlantique, Vannes
Registry updated 2026-10-19
NCT05669989
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
Trial Treatment · Phase 2 · Sanofi
Nantes
Registry updated 2026-10-15
2026-526654-14-01
A Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Trial Treatment · Phase 3 · Janssen Cilag International
Centre Hospitalier Universitaire de Lille, Lille · Institut Paoli-Calmettes, Marseille · Centre Hospitalier Universitaire De Montpellier, Montpellier Cedex 5 · CHRU De Nancy, Nancy Cedex · Centre Hospitalier Universitaire de Nantes, Nantes · Assistance Publique Hopitaux de Paris, Paris · Centre Hospitalier Universitaire de Bordeaux, Pessac · Hospices Civils de Lyon, Pierre-Bénite · Centre Hospitalier Universitaire de Poitiers, Poitiers · Institut Curie, Saint-Cloud · Centre Hospitalier Universitaire De Toulouse, Toulouse Cedex 9 · Centre Hospitalier Régional Universitaire de Tours, Tours
Registry updated 2026-10-14

All Multiple myeloma trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error